Professor Robert MacLaren is Professor of Ophthalmology at the University of Oxford, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology and Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital. He is also a fellow of the Royal College of Ophthalmologists, fellow and former King James IV Professor of Surgery at the Royal College of Surgeons of Edinburgh, fellow of the American College of Surgeons, fellow of the Higher Education Academy, Bodley fellow of Merton College Oxford and Medical Consultant Advisor to the Royal Navy. Robert’s research expertise includes work on the first potential gene therapy for choroideremia and developing the first potential gene therapy treatment for X-linked Retinitis Pigmentosa (in partnership with Nightstar), and performing the first robotic eye operation (in partnership with Preceyes). As an academic, he has published widely on topics relevant to retinal repair and gene therapy, including lead author papers in Nature, the Lancet, PNAS and the New England Journal of Medicine. He is co-founder and director of Nightstar Therapeutics, Inc. which listed on NASDAQ in October 2017, raising $76.9m net of expenses. Robert received Bachelor of Medicine and Bachelor of Surgery degrees from the University of Edinburgh Medical School and his DPhil from the University of Oxford. Robert is a co-founding principal investigator of OxStem Ocular.